お知らせ お知らせ
News

お知らせ

  • 2022.10.07

    Iriyama N, Miura K, Takahashi H, Nakagawa M, Iizuka K, Hamada T, Koike T, Kurihara K, Endo T, Nakayama T, Hatta Y, Nakamura H

    Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience.

    Leukemia and Lymphoma(IF2.996)

  • 2022.10.07

    中村英樹 日本臨牀 特集シェーグレン症候群 ー診断・治療の最新動向ー(単著) p1654-1660202210月、日本臨牀社

  • 2022.09.12

    Iizuka K, Morishita S, Nishizaki Y, Iizuka Y, Iriyama N, Ochiai T, Yanagisawa N, Yasuda H, Ando J, Gotoh A, Takei M, Hatta Y,  Nakamura H, Nakayama T, Komatsu N

    Von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well-controlled platelet counts

    European Journal of Haematology (IF:3.674)

     

  • 2022.09.08

    Takei M, Kitamura N, Nagasawa Y, Tsuzuki H, Iwata M, Nagatsuka Y, Imai K, Fujiwara S,

    Nakamura H

    Are viral infections key inducers of autoimmune diseases?-Focus on Epstein-Barr virus-
    Viruses, accepted (IF: 5.818)

     

     

     

  • 2022.07.27

     

    • 中村英樹 Sjögren症候群 リウマチ病学テキスト、p209-17, 2022年5月、南江堂
    • 八田善弘 専門医のための血液学(共著)、2022年3月、医学書院
  • 2022.07.23
    • Takahashi H, Miura K, Nakagawa M. et al.  Pirarubicin-based intensive chemotherapy followed by consolidative high-dose chemotherapies for peripheral T-cell lymphomas: A noncomparative phase 2 study.  Hematol Oncol. Online ahead of print.
    • Tsuboi H, Nakamura H, Takei M et al. Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren’s Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren’s Syndrome Endocrinopathy) and ROSE II trials. Mod Rheumatol. Online ahead of print.
    • Nakamura H, Nagasawa Y, Kobayashi H. et al.  Successful Treatment of SARS-CoV-2 Vaccination-related Activation of Rheumatoid Arthritis with Positive Findings for Epstein-Barr Virus. Intern Med. 2022 Jul 1;61(13):2073-2076.
    • Miura K, Takahashi H, Nakagawa M. et al.  Ideal dose intensity of R-CHOP in diffuse large B-cell lymphoma.  Expert Rev Anticancer Ther. 2022 Jun;22(6):583-595.
    • Asatani S, Kobayashi H, Nagasawa Y. et al.  Successful treatment for eosinophilic granulomatosis with polyangiitis causing severe myocarditis followed by cardiac magnetic resonance. Mod Rheumatol Case Rep. 2022 Jun 24;6(2):248-253.
    • Iriyama N, Miura K, Uchino Y. et al.  Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia. Chemotherapy. 2022;67(2):96-101.
    • Nakamura H, Tsukamoto M, Nagasawa Y. et al.  Does HTLV-1 Infection Show Phenotypes Found in Sjögren’s Syndrome? Viruses. 2022 Jan 6;14(1):100.
    • Tsutsumi D, Hayama T, Miura K, et al. A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. Int J Clin Pharm. 2022 Apr;44(2):366-373.
    • Yasuda T, Sanada M, Kawazu M, et al. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutation. Blood. 2022 Mar 24;139(12):1850-1862.
    • Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022 Jan 25;6(2):624-636.
  • 2022.07.13
    ホームページをリニューアルしました。スマートフォンにも対応しているので是非ご覧ください